With a total budget of €3.7 million over 36 months, the supported program aims to scale up the SIGNATURA drug ...
LYON, FRANCE (May 27, 2020) - Signia Therapeutics announced today that it has received a grant of € 2.38 millionfrom the E ...
SIGNIA THERAPEUTICS will be in San Francisco fo ...
Signia Therapeutics, Cynbiose and the VirPath academic laboratory are partnering on an ambitious collaborative R&D project to adv ...
Appointment of a Chief Business officer for Signia Therapeutics It is with a great pleasure that Signia Therapeutics announces the ar ...
Very pleased to announce that Dr. Andrés Pizzorno - Signia Therapeutics’ cofounder and Project Manager - has been invited by the Sc ...
Signia Therapeutics is very proud to announce it has been awarded with the label “French Tech Seed” by a wide and independent eval ...
Signia Therapeutics announces it has been selected to present its strategy based on clinical gene expression infection signatures to t ...
Signia Therapeutics announces it has been invited to present company and update of development at the upcoming 6th ISIRV-AVG “Advan ...
Signia Therapeutics announces an agreement with SANOFI to evaluate potential pipeline candidates LYON, FRANCE (November 1, 2018) ...
Signia Therapeutics announces the nomination of Dr. Philippe Personne as CEO, effective as of 1st of October. Dr. Personne graduate ...
Signia Therapeutics is pleased to announce that it will participate at the Bio Europe partnering conference in Copenhagen on November ...
Signia therapeutics.com - Copyright 2021. All right reserved.